Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 1/20 | 0.36 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | PPARG | P37231 | 4/20 | 0.36 |
| ▸ | PPARA | Q07869 | 4/20 | 0.36 |
| ▸ | PPARD | Q03181 | 2/20 | 0.36 |
| ▸ | CTSS | P25774 | 3/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12893341 | 0.92 | PPARA (0.42) | PPARGPPARAPPARDCTSSCTSK | |
| SCHEMBL10045911 | 0.81 | ITGA4 (0.38) | ITGA4ITGB7AAK1KMT2A | |
| SCHEMBL10045871 | 0.77 | KMT2A (0.46) | KDM4EHSD17B10MEN1HPGDKMT2A | |
| SCHEMBL12779903 | 0.71 | CTSK (0.34) | CTSKAAK1MEN1KMT2ACYP1A2 | |
| SCHEMBL6723581 | 0.70 | ELANE (0.44) | KDM4EHSD17B10MEN1HPGDKMT2A | |
| SCHEMBL4731573 | 0.70 | HSD17B10 (0.63) | KDM4EHSD17B10MEN1HPGDKMT2A | |
| SCHEMBL642837 | 0.69 | ELANE (0.43) | KDM4EHSD17B10HPGDKMT2ALMNA | |
| SCHEMBL24073320 | 0.69 | SYK (0.54) | PPARACTSSCTSK | |
| SCHEMBL7290254 | 0.69 | CTSK (0.54) | PPARACTSSCTSK | |
| SCHEMBL1282947 | 0.68 | HSD17B10 (0.50) | KDM4EHSD17B10HPGDKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114858-B2 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2012-02-14 | — | — | US | disclosed |
| US-8114857-B2 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2012-02-14 | — | — | US | disclosed |
| US-20110130368-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC. (CA) | 2011-06-02 | — | — | US | disclosed |
| US-20110098257-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC. (CA) | 2011-04-28 | — | — | US | disclosed |
| US-7910568-B2 | Inflammatory bowel disease, irritable bowel syndrome, Crohn's disease, ulcerative colitis, gastrointestinal disorders; prevention/treatment of colon cancer; releases hydrogen sulfide | ANTIBE THERAPEUTICS INC. (CA) | 2011-03-22 | — | — | US | disclosed |
| US-7879827-B2 | such as 5-amino-2-(2-Acetylamino-3-mercapto-propionyloxy)-benzoic acid, useful for the treatment of gastrointestinal disorders such as inflammatory bowel disease and irritable bowel syndrome, and for the prevention/treatment of colon cancer | ANTIBE THERAPEUTICS INC. (CA) | 2011-02-01 | — | — | US | disclosed |
| US-20090233886-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC. (CA) | 2009-09-17 | — | — | US | disclosed |
| US-7498355-B2 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2009-03-03 | — | — | US | disclosed |
| US-20080207564-A1 | Derivaitves of 4-Or 5-Aminosalicylic Acid | ANTIBE THERAPEUTICS INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20070197479-A1 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197479-A1 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098257-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | CBS, SI, APC | ITGA4 2052/4885ITGB7 3176/4885EPHX2 1216/4885 |
| US-20080207564-A1 | Derivaitves of 4-Or 5-Aminosalicylic Acid | CBS, SI, TST | ITGA4 1519/4885ITGB7 3530/4885EPHX2 1640/4885 |
| US-20090233886-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | CBS, SI, APC | ITGA4 2052/4885ITGB7 3176/4885EPHX2 1216/4885 |
| US-20110130368-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | CBS, SI, APC | ITGA4 2052/4885ITGB7 3176/4885EPHX2 1216/4885 |
| US-20070197479-A1 | Derivatives of 4- or 5-aminosalicylic acid | CBS, SI, APC | ITGA4 2052/4885ITGB7 3176/4885EPHX2 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.